AZD5904

AZD5904 is a potent and selective small molecule inhibitor of human myeloperoxidase (MPO), acting irreversibly with an IC50 of approximately 140 nM. It demonstrates similar potency in mouse and rat models. The compound was originally developed by AstraZeneca for inflammatory and oxidative stress-related conditions such as multiple sclerosis and chronic obstructive pulmonary disease (COPD), but its clinical development for these indications has been discontinued. More recently, it has shown promise in preclinical studies for improving sperm function under oxidative stress conditions, suggesting potential as a novel treatment for male infertility—a significant unmet medical need. In vitro studies have demonstrated that AZD5904 can enhance sperm penetration in a subset of samples exposed to oxidative stress[1][5][6][8]. The drug is orally bioavailable and has undergone Phase 1 clinical trials with no major safety or tolerability concerns identified[1][6]. Development efforts are now led by Conduit Pharmaceuticals following licensing from AstraZeneca[6][7].

Other names

UNII-62A9CG81VNUNII62A9CG81VNUNII 62A9CG81VN62A9CG81VN3-[[(2R)-oxolan-2-yl]methyl]-2-sulfanylidene-7H-purin-6-one